Sanofi (SNW STU) stock market data APIs
€82.989
-0.01(-0%)
as of July 11, 2025
Try our APIs with
free plan!
Sanofi Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for SNW.SG.
Prev. Close
82.989
Open
82.9771
High
84.5958
Low
82.4077
52 wk Range
79.7385-106.1392
Market Cap
108 619 M
EPS
1.79
Dividends (Yield)
0.0368
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sanofi data using free add-ons & libraries
Get Sanofi Fundamental Data
Sanofi Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-24
- EPS/Forecast: 1.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sanofi News
New
Regeneron, Sanofi announce FDA approval of Dupixent for CSU
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older with ch...
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Regeneron Pharmaceuticals, Inc. Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and a...
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Sanofi Winthrop Industrie Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent si...
Stocks to watch next week: Tesla, Alphabet, Intel, Boeing and Unilever
As the latest earnings season gets well underway, there are a range of big-name companies due to report in the coming week. Two Magnificent 7 companies are reporting next week, with Elon Musk's Tesla...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
